Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL3138505

O=S(=O)(O)C(F)(F)F.OC1=CCCCC1

nearest known ligand 0.32

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
ALDH1A1 P00352 1/20 0.31
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15214822 0.79 HDAC4 (0.30) HDAC4HDAC2HDAC8HDAC6
SCHEMBL1381818 0.78
SCHEMBL27610339 0.78 HDAC4 (0.39) HDAC4HDAC2HDAC8HDAC6
SCHEMBL261715 0.78
SCHEMBL3404645 0.76 HDAC4 (0.38) HDAC4HDAC2HDAC8HDAC6ALOX15
SCHEMBL6055452 0.76 HDAC4 (0.38) HDAC4HDAC2HDAC8HDAC6ALOX15
SCHEMBL3888069 0.76
SCHEMBL6897016 0.76 HDAC4 (0.38) HDAC4HDAC2HDAC8HDAC6ALOX15
SCHEMBL1379861 0.76
SCHEMBL3404642 0.76 HDAC4 (0.38) HDAC4HDAC2HDAC8HDAC6ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112479984-B Method for synthesizing enol trifluoromethanesulfonate 湖北航天化学技术研究所 2022-12-13 CN disclosed
CN-112479984-A Method for synthesizing enol trifluoromethanesulfonate 湖北航天化学技术研究所 2021-03-12 CN disclosed
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C HDAC4 3327/4885HDAC2 1405/4885HDAC8 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.